Scarica l'app Stockscreener
28.20
0.19%
-0.055
Precedente Chiudi:
$28.25
Aprire:
$28.35
Volume 24 ore:
997.86K
Relative Volume:
0.82
Capitalizzazione di mercato:
$3.55B
Reddito:
$236.00M
Utile/perdita netta:
$-369.00M
Rapporto P/E:
-8.8586
EPS:
-3.1828
Flusso di cassa netto:
$-489.00M
1 W Prestazione:
-0.79%
1M Prestazione:
-8.55%
6M Prestazione:
+34.01%
1 anno Prestazione:
+208.82%
Intervallo 1D:
$27.25
$28.37
Intervallo di 1 settimana:
$26.19
$29.63
Portata 52W:
$8.84
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
28.20 | 3.50B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arcus Biosciences Inc (RCUS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Three new Arcus employees receive options and 6,300 restricted stock units - Stock Titan
RCUS|Arcus Biosciences Inc|Price:27.850|Chg%:-0.570 - TradingKey
Arcus Biosciences Inc (RCUS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcus Biosciences Inc (RCUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Arcus Biosciences Inc (RCUS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Price to earnings forward of Arcus Biosciences, Inc. – NYSE:RCUS - TradingView
Price to sales forward of Arcus Biosciences, Inc. – NYSE:RCUS - TradingView
RCUS|Arcus Biosciences Inc|Price:28.430|Chg%:-1.300 - TradingKey
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo! Finance Canada
ETFs Investing in Arcus Biosciences, Inc. Stocks - TradingView
Arcus: 'Buy' Casdatifan Late-Stage ccRCC Advancement And 1st-Line Expansions (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences Inc (RCUS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Wedbush Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $41 - Moomoo
H.C. Wainwright reiterates Arcus Biosciences stock rating at buy By Investing.com - Investing.com Canada
Why Did Arcus Biosciences (NYSE:RCUS) Announce New Trial? - Kalkine Media
Arcus Biosciences (RCUS) Partners with Summit Therapeutics for K - GuruFocus
Arcus Biosciences (RCUS) Forms Clinical Supply Agreement with AV - GuruFocus
Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration - TradingView
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer - marketscreener.com
Arcus Biosciences to host Q2 2026 financial results call - scanx.trade
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Arcus Biosciences to Discuss Cancer and Autoimmune Pipeline Aug. 5 - Stock Titan
(RCUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%? - Benzinga
Arcus Biosciences Jumps 5.5% After HC Wainwright & Co. Maintains Buy - AlphaStreet
RCUS Maintained by HC Wainwright & Co. -- Price Target Raised to $45 - GuruFocus
H.C. Wainwright raises Arcus Biosciences stock price target to $45 By Investing.com - Investing.com Canada
Arcus Biosciences (RCUS) Proxy filing Summary - Quartr
This Insider Has Just Sold Shares In Arcus Biosciences - simplywall.st
Arcus Biosciences President Sells 68,569 Shares in July 2026 - sekbernews.id
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run - The Motley Fool
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run - The Motley Fool
Arcus Biosciences (RCUS) president trades 68,569 shares under 10b5-1 plan - Stock Titan
Arcus Biosciences president Juan C. Jaen sells $2.03m in shares - Investing.com Canada
Form 4 Arcus Biosciences Inc For: 13 July By Investing.com - Investing.com UK
Form 144 Arcus Biosciences For: 9 July By Investing.com - Investing.com Nigeria
Trust files proposed RCUS Class A sales (RCUS) — multiple dates and amounts - Stock Titan
Arcus Biosciences awards stock options to five new employees - Stock Titan
Arcus Biosciences grants options and RSUs to new employees - scanx.trade
Arcus Biosciences (RCUS) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer - AOL.com
Arcus Biosciences Announces New Employment Inducement Grants - AOL.com
Arcus Biosciences (RCUS) Surges 4.88% as Shares Test Key Resistance LevelThematic ETF Flow - dars.gov.et
Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus - Sahm
How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data - Sahm
Arcus Biosciences (RCUS) Surges 4.88%: Momentum Builds Near ResistanceFactor ETF Flow - dars.gov.et
Arcus Biosciences stock extends recent pullback as technical signals favor stabilization - Traders Union
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Yahoo Finance
RCUSArcus Biosciences Inc Latest SEC Filings - Finviz
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arcus Biosciences Inc Azioni (RCUS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jaen Juan C. | President |
Jul 10 '26 |
Sale |
28.62 |
20,067 |
574,288 |
822,240 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):